secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2026-10-14T12:52:13+00:00
Accession:  0001193125-26-421076
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Aptevo to present CD40-directed multispecific platform at SITC 2026, Nov 4-8 in Phoenix
--------------------------------------------------------------------------------

- Abstract 1060, "Leveraging multispecific antibody-like molecules to localize CD40 agonism to the tumor," to be presented by Michelle Nelson, PhD, at SITC 2026 in Phoenix.
- Presentation covers Aptevo's broader CD40-directed multispecific portfolio, designed to combine innate and adaptive immune activation within the tumor microenvironment.
- Company says tumor-directed CD40-activating molecules localize immune activation at the tumor while seeking to limit systemic immune activation.
- CSO Mary Janatpour, PhD, cited the work as continued evolution of the multispecific platform targeting persistent solid-tumor challenges.
- Slides to be posted on Aptevo's website Publications page after the November 4-8, 2026 meeting; no clinical data or timelines disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526421076/0001193125-26-421076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526421076/apvo-20261014.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-421076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer